Navigation Links
InterMune Reports First Quarter 2011 Financial Results and Business Highlights
Date:4/28/2011

rs: T.E. King, C. Albera, R.M. du Bois, W. Bradford, U. Costabel, P.W. Noble, S.A. Sahn, D. Valeyre, p.A5302
  • Presentation: Tuesday, May 17, 3:15 p.m., Korbel Ballroom 2A-3A (Lower Level), Colorado Convention Center
  • This presentation will include analyses of lung function change at one year from three Phase 3 studies and these analyses show a clinically meaningful and statistically significant pirfenidone treatment effect at this time point.
  • B102 Poster Discussion: 110. The Effect of Treatment with Pirfenidone on Progression-Free Survival in Patients with Idiopathic Pulmonary Fibrosis (IPF): Exploratory Analysis of Outcomes Using Novel Criteria for Disease Progression
  • Authors: S.A. Sahn, C. Albera, R.M. du Bois, W. Bradford, U. Costabel, T.E. King, P.W. Noble, D. Valeyre, p.A3810
  • Poster Viewing and Discussion: Monday, May 16, - 2:00 p.m. - 4:30 p.m., Korbel Ballroom 1A-1B (Lower Level), Colorado Convention Center

  • Hepatology:

  • In January 2011, InterMune announced that it had reached a new agreement with Roche that will focus on research to identify and develop next-generation protease inhibitors for the treatment of HCV.  Under terms of the agreement, Roche will fund all research costs related to the programs for the term of the agreement, July 1, 2010 to June 30, 2011.

  • First Quarter 2011 Financial Results (Unaudited)InterMune reported total revenue in the first quarter of 2011 of $6.4 million, compared with $6.1 million in the first quarter of 2010, reflecting increased collaboration revenue under the company's new research agreement with Roche, partially offset by lower off-label physician prescriptions of Actimmune® (interferon gamma-1b) for the treatment of IPF, which InterMune does not promote.

    Research and development (R&D) expenses in the first quarter of 2011 were $16.8 million compared with $20.5 million in the first quarter of 2010. 
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. InterMune to Present at Canaccord Adams Conference
    2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
    3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
    4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
    5. InterMune to Release Third Quarter 2008 Financial Results on November 6
    6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
    7. InterMune to Present at Deutsche Bank Biotech Boston Confab
    8. InterMune to Present at J.P. Morgan Healthcare Conference
    9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
    10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Eckert & ... Mass Spectrometry (AMS) services to the pharmaceutical and biotech ... joined the company in the position of Director of ... of broad and valuable experience in drug metabolism and ...
    (Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
    (Date:1/22/2015)... zFlo Motion , a US leader in biomechanics software ... a new partner. STT-Systems has developed an impressive ... with offerings in the optical-motion capture, 3D scanning, and industrial ... unit), iSen, is opening eyes around the world. With no ...
    (Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
    Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
    ... Conference Call and Webcast Scheduled --BRISBANE, Calif., April 20 ... InterMune and Pharmasset, Inc. will host a live webcast of ... on Saturday, April 25, 2009, at 7:00 p.m. CEST (1:00 ... Gane, M.D., principal investigator in the INFORM-1 trial. Members ...
    ... (LSE: SHP,NASDAQ: SHPGY ), the global specialty biopharmaceutical company, will announce,first ... Results press release will be issued at: ... ... Live conference call for investors: , Angus Russell, ...
    ... 750 FAST is Presented at AACR 100th Annual MeetingBEDFORD, ... in fluorescence in vivo imaging from research ... FAST ("Fluorescent Activatible Sensor Technology") imaging agent ... drug response in vivo . Newly developed ...
    Cached Biology Technology:InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25 2Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009 2VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo 2VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo 3VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo 4
    (Date:12/17/2014)... 15, 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a ... introduces for the first time a fingerprint sensor in ...
    (Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
    (Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
    Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
    ... in the Journal of Trauma and Acute Care ... spinal cord-injured patients is successful not only in weaning ... to independent respiration, where they could breathe on their ... The stimulation is provided by the Diaphragm Pacing ...
    ... As the Endangered Species Act (ESA) celebrated its 40th anniversary at ... Wildlife Service (USFWS), was mired in controversy. At issue was a ... the List of Endangered and Threatened Wildlife and add the Mexican ... a result, the USFWS sought an independent peer review of the ...
    ... shape might be just as important in a biology lab ... role in the effectiveness of cells grown to repair or ... structures that enable cells to "shape up," researchers at the ... with a way to measure, and more importantly, classify, the ...
    Cached Biology News:Diaphragm pacing in spinal cord injury successful in weaning patients from ventilators 2Diaphragm pacing in spinal cord injury successful in weaning patients from ventilators 3Panel issues report on gray wolf science 2Shape-sifting: NIST categorizes bio scaffolds by characteristic cell shapes 2
    Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
    ... produces output at 470 nm; includes interface cable ... or installed into rack or desktop boxes ... is an LED that produces either pulsed or ... region -- for fluorescence measurements. The source is ...
    ... miRCURY Array LNA microarray slides ... Array microarray slides incorporate Exiqons unique Locked ... sensitivity and excellent mismatch discrimination for short ... on less than 1 g total RNA ...
    ... amber to slightly cloudy liquid. Yellow, ... per set, each containing 10 ml ... the following proportions by weight: 85% ... monooleate emulsifier), and 0.1% Mycobacterium ...
    Biology Products: